Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Imagabalin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 2/20 | 0.38 |
| ▸ | CACNB3 known ✓ | P54284 | 1/20 | 0.38 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.38 |
| ▸ | CACNA2D2 known ✓ | Q9NY47 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | BHMT | Q93088 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imagabalin SCHEMBL3961605 | 1.00 | ALDH1A1 (0.43) | ALDH1A1S1PR2S1PR1SLC1A3SLC1A2 | |
| Imagabalin SCHEMBL2472147 | 1.00 | ALDH1A1 (0.43) | ALDH1A1S1PR2S1PR1SLC1A3SLC1A2 | |
| Imagabalin SCHEMBL1816431 | 1.00 | ALDH1A1 (0.43) | ALDH1A1S1PR2S1PR1SLC1A3SLC1A2 | |
| Imagabalin SCHEMBL3960408 | 1.00 | ALDH1A1 (0.43) | ALDH1A1S1PR2S1PR1SLC1A3SLC1A2 | |
| Imagabalin SCHEMBL3960412 | 1.00 | ALDH1A1 (0.43) | ALDH1A1S1PR2S1PR1SLC1A3SLC1A2 | |
| Imagabalin SCHEMBL5282412 | 0.98 | ALDH1A1 (0.42) | ALDH1A1S1PR2S1PR1SLC1A3SLC1A2 | |
| Imagabalin SCHEMBL4936508 | 0.98 | ALDH1A1 (0.42) | ALDH1A1S1PR2S1PR1SLC1A3SLC1A2 | |
| Imagabalin SCHEMBL1198695 | 0.98 | ALDH1A1 (0.42) | ALDH1A1S1PR2S1PR1SLC1A3SLC1A2 | |
| SCHEMBL3958660 | 0.89 | S1PR2 (0.46) | ALDH1A1S1PR2S1PR1SLC1A3SLC1A2 | |
| SCHEMBL2909702 | 0.89 | S1PR2 (0.46) | ALDH1A1S1PR2S1PR1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 952 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12578348-B2 | Blood indicators of Alzheimer's disease | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2026-03-17 | — | — | US | claimed |
| US-20250382671-A1 | METHODS OF DETECTION AND ANALYSIS OF NUCLEIC ACID IN CIRCULATING BODILY FLUIDS | Brain Chemistry Labs (US) | 2025-12-18 | — | — | US | claimed |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| EP-4287941-A1 | BLOOD INDICATORS OF ALZHEIMER'S DISEASE | The Institute For Ethnomedicine DBA Brain Chemistry Labs (US) | 2023-12-13 | — | — | EP | claimed |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2022-11-03 | — | — | US | claimed |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2022-10-18 | — | — | US | claimed |
| EP-4069868-A2 | METHODS OF DETECTION AND ANALYSIS OF NUCLEIC ACID IN NEURAL-DERIVED EXOSOMES | The Institute For Ethnomedicine DBA Brain Chemistry Labs (US) | 2022-10-12 | — | — | EP | claimed |
| WO-2022168006-A1 | BLOOD INDICATORS OF ALZHEIMER'S DISEASE | The Institute for Ethnomedicine dba Brain Chemistry Labs (US) | 2022-08-11 | — | — | WO | claimed |
| US-20220252620-A1 | BLOOD INDICATORS OF ALZHEIMER'S DISEASE | The Institute for Ethnomedicine dba Brain Chemistry Labs | 2022-08-11 | — | — | US | claimed |
| CN-111630026-A | Sustained release pharmaceutical formulations and methods of treatment | 道格拉斯制药有限公司 | 2020-09-04 | — | — | CN | claimed |
| WO-2005002585-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | claimed |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | claimed |
| EP-1492761-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | claimed |
| US-20040157847-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-08-12 | — | — | US | claimed |
| US-20040143014-A1 | Therapeutic use of alpha-2-delta ligands | PFIZER INC | 2004-07-22 | — | — | US | claimed |
| WO-2004054577-A1 | ALPHA-2-DELTA LIGANDS TO TREAT OCD AND RELATED DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | claimed |
| US-20040092522-A1 | Synergistic combinations | FIELD MARK JOHN (GB) | 2004-05-13 | — | — | US | claimed |
| WO-2004016259-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | claimed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | claimed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | MMP13, MMP10, MMP11 | CACNA2D1 826/4885CACNB3 1002/4885CACNA1C 1180/4885 |
| US-20220347104-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | CRH, HTR5A, NPY5R | CACNA2D1 2679/4885CACNB3 589/4885CACNA1C 1053/4885 |
| US-20040092522-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | CACNA2D1 57/4885CACNB3 119/4885CACNA1C 49/4885 |
| US-20040143014-A1 | Therapeutic use of alpha-2-delta ligands | CHRND, CHRNG, CHRNE | CACNA2D1 1101/4885CACNB3 986/4885CACNA1C 1199/4885 |
| US-11471416-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | CACNA2D1 2679/4885CACNB3 589/4885CACNA1C 1053/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | CACNA2D1 77/4885CACNB3 39/4885CACNA1C 38/4885 |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | CRH, HTR5A, NPY5R | CACNA2D1 2679/4885CACNB3 589/4885CACNA1C 1053/4885 |
| US-12578348-B2 | Blood indicators of Alzheimer's disease | COMT, MAOB, ACHE | CACNA2D1 148/4885CACNB3 30/4885CACNA1C 257/4885 |
| US-20040157847-A1 | Synergistic combinations | PDE2A, PDE1B, PDE1A | CACNA2D1 57/4885CACNB3 119/4885CACNA1C 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.